Market News How it works Learn FAQ
| RCT 0.1382 81.60% | NU 11.97 -21.04% | TGL 0.2617 18.15% | EWZ 32.715 -23.19% | SRTM 0.3394 -21.12% | BBD 2.835 -30.34% | SHFS 0.0989 -25.30% | GCDT 0.1322 -24.93% | ITUB 7.368 -23.81% | NWGL 0.0817 -0.37% | CLRO 4.67 43.69% | XP 14.8623 -51.13% | AZTR 1.265 76.92% | RBNE 0.1664 -12.42% | PBR 21.535 -17.68% | SGRY 23.055 46.38% | SOXL 85.96 2.87% | TSLL 10.8899 11.58% | SPCX 147.535 0.03% | VALE 12.0045 -3.19% | SPRC 1.4499 33.02% | NVD 4.04 -3.58% | CRWV 54.96 1.34% | JBLU 2.2085 -15.87% | SOXS 51.01 -2.76% | INTC 87.29 0.38% | GPUS 0.1679 -0.59% | NVDA 215 1.92% | TSLA 394.1 5.88% | IREN 24.64 -1.06% | ABEV 2.7991 -15.18% | TQQQ 67.83 2.32% | RENT 2.9899 30.00% | NOK 8.46 3.93% | INTR 4.415 -38.60% | PBR-A 18.92 -19.59% | XTND 2.8083 58.66% | SQQQ 38.76 -2.32% | BITO 10.6402 -1.75% | LUCD 0.5437 32.29% | SPDN 8.495 -0.53% | VBIO 0.8098 -13.85% | SBS 4.765 -25.55% | XXII 0.0999 -49.47% | SID 0.9233 -21.75% | STNE 7.96 -30.66% | KORU 10.6 0.19% | WFF 0.0765 -4.38% | RWM 14.4501 -0.69% | TSLG 5.45 11.91%
UBUnity Biotechnology, Inc. logo

Unity Biotechnology, Inc. (UBX)

NASDAQ Global Select · Currency in USD
$0.20 ▲ +0.10 (+92.77%)
As of Sep 4, 4:00 PM ET. Market open.

Summary

Previous Close
$0.10
Open
$0.20
Day's Range
$0.20 – $0.20
52 Week Range
$0.10 – $3.10
Volume
0
Avg. Volume
734,131
Market Cap
$3.44M
Beta (5Y Monthly)
1.06
PE Ratio (TTM)
--
EPS (TTM)
-$1.54
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$2.50

Profile: Unity Biotechnology, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
16
CEO
Anirvan Ghosh

Unity Biotechnology, Inc. is a biotechnology firm specializing in the development of therapeutic solutions aimed at slowing, halting, or even reversing age-associated diseases. Leading its pipeline, the drug candidate UBX1325 is currently undergoing Phase II clinical trials to treat age-related vision disorders, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Additionally, the company is advancing UBX1967 for various ophthalmologic conditions, while UBX2050, a human anti-Tie2 agonist monoclonal antibody, also targets age-related eye diseases.

Earnings

DateEst.Actual
Aug 5, 2025-$0.30-$0.31Miss
Apr 22, 2025-$0.43-$0.43Beat
Mar 7, 2025-$0.42-$0.50Miss
Nov 4, 2024-$0.40-$0.38Beat
Aug 6, 2024-$0.44-$0.31Beat
May 14, 2024-$0.48-$0.34Beat

Analyst view

Consensus price target
$2.50 ▲ +1,149.4%
Range $1.00 – $4.00
Rating: Buy
Buy 70% · Hold 30% · Sell 0%

Get free alerts on UBX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.